2-(2-tritylaminothiazol-4-yl)-2-[(Z)-(2-chloroethoxy)imino]acetic acid | 96630-02-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2-(2-tritylaminothiazol-4-yl)-2-[(Z)-(2-chloroethoxy)imino]acetic acid
• 英文别名: (2Z)-2-(2-chloroethoxyimino)-2-[2-(tritylamino)-1,3-thiazol-4-yl]acetic acid
• CAS: 96630-02-3
• 化学式: C₂₆H₂₂ClN₃O₃S
• 分子量: 491.998
• InChiKey: FVPIIOYRAMPGBJ-WMMMYUQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(2-tritylaminothiazol-4-yl)-2-[(Z)-(2-chloroethoxy)imino]acetic acid 在 N-甲基吗啉 、 三乙基硅烷 、 三氟乙酸 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 3.42h， 生成 (S)-6-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-2-chloro-ethoxyimino]-acetylamino}-2-methanesulfonyl-7-oxo-6,7-dihydro-3H,5H-pyrazolo[1,2-a]pyrazole-1-carboxylic acid allyl ester
  参考文献：
  名称：

  Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters

  摘要：

  The structure-activity relationship among a series of novel pyrazolidinone antibacterial agents is described. Specifically, the effect of modification of the side chain attached to the nitrogen at C-7 was explored in an attempt to improve the potency and spectrum of activity. This approach was successful in identifying several compounds having good in vitro profiles. These top candidates were then evaluated for their activity in vivo, and their pharmacokinetic behavior in various animal models was explored. This information proved critical for the identification of candidates for clinical evaluation.

  DOI：

  10.1021/jm00074a002
• 作为产物：
  描述：

  1-溴-2-氯乙烷 、 ethyl (Z)-2-hydroxyimino-2-(2-triphenylmethylaminothiazol-4-yl)acetate 生成 2-(2-tritylaminothiazol-4-yl)-2-[(Z)-(2-chloroethoxy)imino]acetic acid
  参考文献：
  名称：

  3-substituted-aminomethyl cephalosporin derivatives

  摘要：

  公式I的头孢菌素衍生物：##STR1##其中X是S、O、CH.sub.2或SO，R1是(可选取代)咪唑-2-基或头孢菌素领域已知的C-7酰基之一，R2是氢或甲氧基，R3是羧基或其可生物降解酯，--R4是公式XII、XIII或XIV：##STR2##其中R32-R40包括如规范中定义的；及其盐。还描述了制药组合物、制造方法和中间体。

  公开号：

  US04678781A1

文献信息

• Cephalosporin derivatives
  申请人：Ici Pharma

  公开号：US04855420A1

  公开（公告）日：1989-08-08

  A cephalosporin derivative of the formula I: ##STR1## in which X is S, O, CH.sub.2 or SO, R1 is (optionally-substituted) imidazol-2-yl or one of the C-7 acyl groups known in the cephalosporin art, R2 is hydrogen or methoxy, R3 is carboxy or a biodegradable ester thereof and -R4 is of the formula XII, XIII or XIV: ##STR2## in which R32-R40 inclusive are as defined in the specification; and the salts thereof. Pharmaceutical compositions, methods of manufacture and intermediates are also described.

  一种头孢菌素衍生物，化学式为I：##STR1## 其中X为S，O，CH.sub.2或SO，R1为（可选取代的）咪唑-2-基或头孢菌素艺术中已知的C-7酰基之一，R2为氢或甲氧基，R3为羧基或其生物可降解的酯，-R4为化学式XII，XIII或XIV：##STR2## 在其中R32-R40包括如规范中定义的；以及其盐。还描述了制药组合物、制造方法和中间体。
• US4678781A
  申请人：——

  公开号：US4678781A

  公开（公告）日：1987-07-07
• US4855420A
  申请人：——

  公开号：US4855420A

  公开（公告）日：1989-08-08
• Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters
  作者：Robert J. Ternansky、Susan E. Draheim、Andrew J. Pike、Fred T. Counter、Judy A. Eudaly、Jeffrey S. Kasher

  DOI：10.1021/jm00074a002

  日期：1993.10

  The structure-activity relationship among a series of novel pyrazolidinone antibacterial agents is described. Specifically, the effect of modification of the side chain attached to the nitrogen at C-7 was explored in an attempt to improve the potency and spectrum of activity. This approach was successful in identifying several compounds having good in vitro profiles. These top candidates were then evaluated for their activity in vivo, and their pharmacokinetic behavior in various animal models was explored. This information proved critical for the identification of candidates for clinical evaluation.
• 3-substituted-aminomethyl cephalosporin derivatives
  申请人：ICI Pharma

  公开号：US04678781A1

  公开（公告）日：1987-07-07

  A cephalosporin derivative of the formula I: ##STR1## in which X is S, O, CH.sub.2 or SO, R1 is (optionally-substituted)imidazol-2-yl or one of the C-7 acyl groups known in the cephalosporin art, R2 is hydrogen or methoxy, R3 is carboxy or a biodegradable ester thereof and --R4 is of the formula XII, XIII or XIV: ##STR2## in which R32-R40 inclusive are as defined in the specification; and the salts thereof. Pharmaceutical compositions, methods of manufacture and intermediates are also described.

  公式I的头孢菌素衍生物：##STR1##其中X是S、O、CH.sub.2或SO，R1是(可选取代)咪唑-2-基或头孢菌素领域已知的C-7酰基之一，R2是氢或甲氧基，R3是羧基或其可生物降解酯，--R4是公式XII、XIII或XIV：##STR2##其中R32-R40包括如规范中定义的；及其盐。还描述了制药组合物、制造方法和中间体。